Celsion Corporation (NASDAQ:CLSN) has posted results for the last fiscal year, recording EPS of $-10.21. For this year, EPS is anticipated to grow 17.50% over the preceding year, while next year’s EPS is predicted to increase 42.60%.
The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.
Recently, Celsion Corporation (NASDAQ:CLSN) reported that for the previous five years, EPS at Celsion Corporation has increased 29.80%, while rise sales have surged -24.20% over the same period.
Shares of Celsion Corporation are now trading at $3.20, giving it market cap of $8.29M. Over the last 12 months, shares of Celsion Corporation have risen to maximum of $-83.67% and declined to a minimum of $57.64%.
The stock?s beta, which measures volatility, is 1.03. For the purpose of clarity, note that a beta of less than 1 implies that a stock is less volatile versus the overall market, while a beta over 1 indicates a stock is more volatile over the market.
Celsion Corporation shows 20-Day Simple Moving Average of $7.36% and 50-Day Simple Moving Average of $-6.51%. The 200-Day SMA is $-59.55%.
The stock’s weekly performance is 10.73% while its monthly performance is 3.90%. Year-to-date the equity has moved -24.79% compared to a performance of -83.01%% over the preceding 12 months.
Celsion Corporation has witnessed – insider transactions, showing insider ownership of 0.30%. That compares to 6.60% ownership by institutional investors after -32.15% institutional transactions.
Return on investments in Celsion Corporation for the last 12 months is -229.70%, while return on assets for the equivalent period is -60.30%. Return on equity for the previous 12 months, on the other hand, is -215.40%.
Celsion Corporation has RSI (Relative Strength Index) of 51.99.
Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on June 13, 2017 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Accordingly, Celsion is in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market and NASDAQ considers the matter closed.